Form 8-K - Current report:
SEC Accession No. 0001213900-24-081982
Filing Date
2024-09-26
Accepted
2024-09-26 08:45:07
Documents
17
Period of Report
2024-09-26
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0215731-8k_pasithea.htm   iXBRL 8-K 29039
2 PRESS RELEASE DATED SEPTEMBER 26, 2024 ea021573101ex99-1_pasithea.htm EX-99.1 25878
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6279
4 GRAPHIC ex99-1_002.jpg GRAPHIC 14436
  Complete submission text file 0001213900-24-081982.txt   310807

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ktta-20240926.xsd EX-101.SCH 3810
6 XBRL DEFINITION FILE ktta-20240926_def.xml EX-101.DEF 26681
7 XBRL LABEL FILE ktta-20240926_lab.xml EX-101.LAB 36819
8 XBRL PRESENTATION FILE ktta-20240926_pre.xml EX-101.PRE 25305
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0215731-8k_pasithea_htm.xml XML 5937
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 241326251
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)